Published 07-17-18
Issued by Teva Pharmaceutical
Teva has a rich history of providing innovative, high-quality generic and specialty drugs and health solutions to patients around the world every day. Since joining the company late last year, I’ve been motivated by the opportunity to advance this legacy of promoting health.
A message from our CEO, Kåre Schultz
Teva has a rich history of providing innovative, high-quality generic and specialty drugs and health solutions to patients around the world every day. Since joining the company late last year, I’ve been motivated by the opportunity to advance this legacy of promoting health.
In December 2017, we launched a comprehensive restructuring program, crucial to restoring our financial security and stabilizing our business. We have also strengthened our leadership team and created a new organizational structure. These decisions were not taken lightly, but were necessary to enable us to better serve our patients while maintaining the highest standards of quality, ethics and compliance.
In these times of change, our commitment to Social Impact has not wavered. Social Impact is inherently embedded in our business, as Teva is uniquely positioned to improve health by offering accessible treatments to millions worldwide.
The world is facing dynamic health, environmental and social challenges. Together with our partners and stakeholders, we are committed to evolving and adapting our efforts to effect change in ways that are aligned with our business expertise and resources.
I encourage you to read about our Social Impact progress in this report and look forward to advancing these efforts together.
Kåre Schultz
President & CEO, Teva Pharmaceutical Industries Ltd.
Report Highlights
Teva is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Teva’s “2017 Social Impact Report: Improving Health, Enabling Better Days” spotlights the company’s commitment to corporate responsibility and transparency, and provides context on its efforts to contribute to healthy communities in ways the business can uniquely support—through safe medicines, collaboration, health initiatives and innovative research.
Media Contact Information:
Teva Pharmaceutical Industries Ltd.
IR Contacts
United States
Kevin C. Mannix, (215) 591-8912
or
Israel
Ran Meir, 972 (3) 926-7516
Tomer Amitai, 972 (3) 926-7656
PR Contacts
United States
Elizabeth DeLuca, (267) 468-4329
or
Israel
Yonatan Beker, 972 (54) 888-5898
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.